|Bid||50.50 x 200|
|Ask||56.00 x 100|
|Day's Range||54.09 - 56.36|
|52 Week Range||45.42 - 99.45|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 26, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||93.00|
Clovis Oncology, Inc. will announce its fourth quarter and full year 2017 financial results on Monday, February 26, 2018, after the close of the U.S. financial markets.
AstraZeneca's (AZN) PARP inhibitor, Lynparza, receives approval for treating ovarian cancer in Japan, following its label expansion in the United States.
NEW YORK, NY / ACCESSWIRE / January 12, 2017 / U.S. markets rallied sharply Thursday as investor focus has now shifted to the upcoming earnings season. The Dow Jones Industrial Average jumped 0.81 percent ...
Puma, Clovis and Incyte could outperform other midcap biotechs this year, an analyst says, listing the trio as his favorites for 2018.
Clovis Oncology, Inc. today announced that its Chief Executive Officer and President, Patrick J. Mahaffy, will present at the 36th Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2018 at 2:30 PM Pacific Time.
Short interest is moderate for CLVS with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.
Clovis Oncology (CLVS) stock is rapidly gaining momentum. The company's only approved drug Rubraca is off to an impressive start and is nearing label expansion approval.
Clovis Oncology, Inc. announced today that the European Union’s European Medicines Agency Committee for Medicinal Products for Human Use has requested that the Scientific Advisory Group on Oncology provide an opinion on aspects of the ongoing Marketing Authorization Application relating to a potential conditional approval for rucaparib.
Clovis Oncology shows rising price performance, earning an upgrade to its IBD Relative Strength Rating
The FDA grants priority review to Clovis' (CLVS) supplemental new drug application for its marketed drug, Rubraca's label expansion as a maintenance treatment for ovarian cancer.
Clovis rose Wednesday to the detriment of Tesaro and AstraZeneca after the FDA accepted its application for expanded use of its PARP inhibitor known as Rubraca.
The FDA has accepted the Boulder, Colo.-based firm's supplemental New Drug Application for ovarian cancer therapy rucaparib and granted priority review status to the application.
Data presentations and regulatory updates were the key highlights this week with companies like AbbVie (ABBV) and Clovis providing data on their pipeline candidates.
The U.S. Food and Drug Administration has granted a fast-tracked review of using a Clovis Oncology drug to treat a wider range of ovarian cancer patients. The Boulder-based company (CLVS) seeks approval to use its ovarian cancer drug, rucaparib, as a maintenance treatment in women “with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are platinum sensitive” and regardless of their genetic profile. The FDA says it will make a decision by April 6, 2018, Clovis announced Tuesday.
Clovis Oncology announced today that the U.S. Food and Drug Administration has accepted the company’s supplemental New Drug Application for rucaparib and granted priority review status to the application with a Prescription Drug User Fee Act date of April 6, 2018.
After a very strong year, the biotech sector has suffered an 8% pullback over the past 5 weeks. Todd Hagopian, whose biotech portfolio is up 38% this year, believes that the recent pullback has created bargains in Alexion, Flexion, Clovis, Tesaro, and Incyte.
Short interest is moderate for CLVS with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. The net inflows of $2.97 billion over the last one-month into ETFs that hold CLVS are not among the highest of the last year and have been slowing.
Three companies including a major pharma player are developing drugs for the treatment of ovarian cancer using a new technology instead of chemotherapy and competing to gain market share.
TESARO (TSRO) received a boost with the approval of Zejula in Europe for ovarian cancer, following its approval in the United States earlier this year.
NEW YORK, NY / ACCESSWIRE / November 20, 2017 / U.S. markets closed in the red Friday, with the Dow Jones and S&P 500 posting their second consecutive weekly loss, as concerns regarding President Trump's ...
Short interest is moderate for CLVS with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last month, ETFs holding CLVS are favorable, with net inflows of $3.51 billion.